417 related articles for article (PubMed ID: 25013535)
1. Diagnostic and prognostic biomarkers in melanoma.
Weinstein D; Leininger J; Hamby C; Safai B
J Clin Aesthet Dermatol; 2014 Jun; 7(6):13-24. PubMed ID: 25013535
[TBL] [Abstract][Full Text] [Related]
2. Clinical application and limitations of the fluorescence in situ hybridization (FISH) assay in the diagnosis and management of melanocytic lesions: a report of 3 cases.
Nijhawan RI; Votava HJ; Mariwalla K
Cutis; 2012 Oct; 90(4):189-95. PubMed ID: 23259206
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence in-situ hybridization analysis for melanoma diagnosis.
Senetta R; Paglierani M; Massi D
Histopathology; 2012 Apr; 60(5):706-14. PubMed ID: 22007736
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi.
Gerami P; Wass A; Mafee M; Fang Y; Pulitzer MP; Busam KJ
Am J Surg Pathol; 2009 Dec; 33(12):1783-8. PubMed ID: 19809275
[TBL] [Abstract][Full Text] [Related]
5. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
6. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
7. Histopathological evaluation of cutaneous malignant melanoma: A retrospective study.
Gheoca Mutu DE; Avino A; Balcangiu-Stroescu AE; Mehedințu M; Bălan DG; Brîndușe LA; Popescu AM; Ionescu D; Cristea BM; Tomescu LF; Jecan CR; Răducu L
Exp Ther Med; 2022 Jun; 23(6):402. PubMed ID: 35601077
[TBL] [Abstract][Full Text] [Related]
8. What's new in prognostication of melanoma in the dermatopathology laboratory?
Bangash HK; Romegialli A; Dadras SS
Clin Dermatol; 2013; 31(3):317-23. PubMed ID: 23608451
[TBL] [Abstract][Full Text] [Related]
9. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization as an ancillary tool in the diagnosis of ambiguous melanocytic neoplasms: a review of 804 cases.
North JP; Garrido MC; Kolaitis NA; LeBoit PE; McCalmont TH; Bastian BC
Am J Surg Pathol; 2014 Jun; 38(6):824-31. PubMed ID: 24618603
[TBL] [Abstract][Full Text] [Related]
11. The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers.
Quiohilag K; Caie P; Oniscu A; Brenn T; Harrison D
Virchows Arch; 2020 Jul; 477(1):121-130. PubMed ID: 32388720
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
[TBL] [Abstract][Full Text] [Related]
13. Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy.
Scolyer RA; Murali R; McCarthy SW; Thompson JF
Arch Pathol Lab Med; 2010 Dec; 134(12):1770-7. PubMed ID: 21128774
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal copy number analysis in melanoma diagnostics.
North JP; Vemula SS; Bastian BC
Methods Mol Biol; 2014; 1102():199-226. PubMed ID: 24258981
[TBL] [Abstract][Full Text] [Related]
15. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
16. WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi.
Rosner K; Mehregan DR; Moussai D; Abrams J; Tromp G; Mehregan DA
J Cutan Pathol; 2009 Oct; 36(10):1077-82. PubMed ID: 19615003
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
18. Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.
Dundr P; Simon K; Němejcová K; Bártů M; Tichá I; Michálková R; Jakša R; Věcková Z; Kodet O
Melanoma Res; 2019 Apr; 29(2):157-162. PubMed ID: 30422880
[TBL] [Abstract][Full Text] [Related]
19. Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization.
Busam KJ; Fang Y; Jhanwar SC; Pulitzer MP; Marr B; Abramson DH
J Cutan Pathol; 2010 Feb; 37(2):196-203. PubMed ID: 20100177
[TBL] [Abstract][Full Text] [Related]
20. Black and Brown Oro-facial Mucocutaneous Neoplasms.
Natarajan E
Head Neck Pathol; 2019 Mar; 13(1):56-70. PubMed ID: 30693458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
